Symmetry Partners LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,144 shares of the biopharmaceutical company’s stock, valued at approximately $278,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after purchasing an additional 287,064 shares during the period. Robeco Institutional Asset Management B.V. lifted its stake in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 12,513 shares in the last quarter. Quattro Financial Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 2,517.8% in the 1st quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock worth $747,000 after purchasing an additional 4,809 shares during the period. Westpac Banking Corp grew its holdings in shares of Alnylam Pharmaceuticals by 59.8% during the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 566 shares in the last quarter. Finally, Plato Investment Management Ltd increased its holdings in shares of Alnylam Pharmaceuticals by 2,666.3% in the 1st quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock valued at $674,000 after purchasing an additional 4,346 shares during the period. Institutional investors own 92.97% of the company’s stock.
Alnylam Pharmaceuticals Stock Down 0.3 %
Shares of ALNY stock traded down $0.94 on Friday, reaching $269.52. The company’s stock had a trading volume of 529,266 shares, compared to its average volume of 898,002. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $274.93. The stock’s 50 day simple moving average is $220.68 and its 200-day simple moving average is $177.41. The company has a market capitalization of $34.09 billion, a P/E ratio of -100.57 and a beta of 0.37.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the company. Royal Bank of Canada boosted their price target on Alnylam Pharmaceuticals from $265.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $160.00 to $248.00 and gave the company a “neutral” rating in a research report on Wednesday, July 3rd. Evercore ISI increased their price target on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 25th. Cantor Fitzgerald boosted their target price on shares of Alnylam Pharmaceuticals from $150.00 to $220.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Finally, Chardan Capital reaffirmed a “buy” rating and set a $225.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, May 3rd. Eight analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $269.32.
View Our Latest Report on ALNY
Insiders Place Their Bets
In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,148 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at $19,829,070. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. Insiders have sold 109,848 shares of company stock valued at $24,683,444 in the last ninety days. Company insiders own 1.50% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Recommended Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- MarketBeat Week in Review – 8/5 – 8/9
- Best Stocks Under $10.00
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Basic Materials Stocks Investing
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.